Many thanks for this news. Really encouraging. It is actually a FDA approval for a novel use of an existing drug.
No reason by ESSI cannot achieve the same. In our case ESSI is a USA-corporation and it is USPTO mission to help USA firms succeed (readers can read the excellent blog of the USPTO Director).
I got into PRTN and now ESSI precisely because I like its novel usage which in our case is already being prescribed to patients as that is allowed by FDA for an approved drug.
So why is ESSI dragging its feet on the FDA trials? They are sitting on a goldmine.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.